Paloma Partners’s Genocea Biosciences, Inc. GNCA Stock Holding History

Paloma Partners’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,112	Closed	-$343K	–	2124
2018 Q2	$343K	Buy	+50,112	New	+$375K	0.01%	1210
2016 Q3	–	Sell	-10,187	Closed	-$334K	–	2286
2016 Q2	$334K	Buy	+10,187	New	+$373K	﹤0.01%	1720

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's GNCA Position: Q3 2018 in Review

Paloma Partners sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2018, closing a stake of 50,112 shares — an estimated $343K sold.

Paloma Partners first reported a position in GNCA in Q2 2016 and held it in 2 quarters. The position peaked at $343K in Q2 2018. 48 funds tracked by Wall St. Rank hold GNCA as of Q3 2018.

Paloma Partners reported no remaining Genocea Biosciences, Inc. position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 50,112 Genocea Biosciences, Inc. shares in Q3 2018, an estimated $343K.
Paloma Partners first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 2 quarters.
Paloma Partners's Genocea Biosciences, Inc. position peaked at $343K in Q2 2018.
48 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.